Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

NCT01493479 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: 90Y Ibritumomab tiuxetan
DRUG: Rituximab

Sponsor

The Christie NHS Foundation Trust

Collaborators

[object Object]